Robert R. Ruffolo - 10 Sep 2025 Form 3 Insider Report for LB PHARMACEUTICALS INC

Reporting relationship: Director
Issuer ticker: LBRX on Nasdaq
Reported as of: 10 Sep 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 10 Sep 2025, 19:20:39 UTC
Prior SEC filing: 20 May 2025
Next SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Marc Panoff, Attorney-in-Fact

Key filing fact

Robert R. Ruffolo filed Form 3 for LB PHARMACEUTICALS INC on 10 Sep 2025.

Key facts

This page summarizes Robert R. Ruffolo's Form 3 filing for LB PHARMACEUTICALS INC.
0 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 10 Sep 2025, 19:20.

Change

Previous filing in this sequence was filed on 20 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001187308 Primary reporting owner

RUFFOLO ROBERT R

Relationship: Director
Address: C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK
Signature: /s/ Marc Panoff, Attorney-in-Fact
Signature date: 10 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,365
Date: 10 Sep 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LBRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 10 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,792
Exercise price: $69.72
Footnotes: F2

LBRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 10 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 717
Exercise price: $69.72
Footnotes: F2

LBRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 10 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,757
Exercise price: $41.84
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Includes 1,792 shares of restricted stock which shall vest six months from the closing date of the Issuer's initial public offering.

Footnote F2

Immediately exercisable.

Footnote F3

One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.